[1]LJUNGBERG B,ALBIGES L,ABU-GHANEM Y,et al.European association of urology guidelines on renal cell carcinoma:The 2019 update［J］.Eur Urol,2019,75(5):799-810.
[2]SIEGEL RL,MILLER KD,FUCHS HE,JEMAL A.Cancer statistics,2021［J］.CA:A Cancer Journal for Clinicians,2021,71(1):7-33.
[3]ESCUDIER B,PORTA C,SCHMIDINGER M,et al.Renal cell carcinoma:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up［J］.Ann Oncol,2017,28(suppl-4):iv167-iv168.
[4]WADDELL T,FIFE K,GRIFFITHS R,et al.Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy:a UK retrospective cohort study［J］.BMC Cancer,2022,22(1):617.
[5]PEREIRA B,BILLAUD M,ALMEIDA R.RNA-binding proteins in cancer:Old players and new actors［J］.Trends Cancer,2017,3(7):506-528.
[6]KUNDU A,NAM H,SHELAR S,et al.PRDM16 suppresses HIF-targeted gene expression in kidney cancer［J］.J Exp Med,2020,217(6):e20191005.
[7]SYAFRUDDIN SE,RODRIGUES P,VOJTASOVA E,et al.A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma［J］.Nat Commun,2019,10(1):1152.
[8]XIAO ZD,HAN L,LEE H,et al.Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development［J］.Nat Commun,2017,8(1):783.
[9]JONAS K,CALIN GA,PICHLER M.RNA-binding proteins as important regulators of long non-coding RNAs in cancer［J］.Int J Mol Sci,2020,21(8):2969.
[10]WANG B,ZHAO H,NI S,et al.Integrated analysis of the roles of RNA binding proteins and their prognostic value in clear cell renal cell carcinoma［J］.J Healthc Eng,2021:5568411.
[11]MASUDA K,KUWANO Y.Diverse roles of RNA-binding proteins in cancer traits and their implications in gastrointestinal cancers［J］.Wiley Interdiscip Rev RNA,2019,10(3):e1520.
[12]LI X,ZHOU X,HUA F,et al.The RNA-binding protein Sam68 is critical for non-small cell lung cancer cell proliferation by regulating Wnt/β-catenin pathway［J］.Int J Clin Exp Pathol,2017,10(8):8281-8291.
[13]LIANG G,MENG W,HUANG X,et al.miR-196b-5p-mediated downregulation of TSPAN12 and GATA6 promotes tumor progression in non-small cell lung cancer［J］.Proc Natl Acad Sci USA,2020,117(8):4347-4357.
[14]LEGRAND N,DIXON DA,SOBOLEWSKI C.AU-rich element-binding proteins in colorectal cancer［J］.World J Gastrointest Oncol,2019,11(2):71-90.
[15]CHATTERJI P,RUSTGI AK.RNA binding proteins in intestinal epithelial biology and colorectal cancer［J］.Trends Mol Med,2018,24(5):490-506.
[16]GARCIA-CARDENAS JM,GUERRERO S,LOPEZ-CORTES A,et al.Post-transcriptional regulation of colorectal cancer:A focus on RNA-binding proteins［J］.Front Mol Biosci,2019,6:65.
[17]DENG Y,LI X,JIANG W,et al.SNRPB promotes cell cycle progression in thyroid carcinoma via inhibiting p53［J］.Open Med(Wars),2022,17(1):1623-1631.
[18]ZHANG RL,YANG JP,PENG LX,et al.RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA［J］.Cell Cycle,2016,15(22):3094-3104.
[19]BANDOPADHAYAY P,RAMKISSOON LA,JAIN P,et al.MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism［J］.Nat Genet,2016,48(3):273-282.
[20]SHI F,WEI D,ZHU Z,et al.The RNA-binding protein QKI suppresses tumorigenesis of clear cell renal cell carcinoma by regulating the expression of HIF-1α［J］.J Cancer,2020,11(6):1359-1370.
[21]ZHENG L,ZHANG Z,ZHANG S,et al.RNA binding protein RNPC1 inhibits breast cancer cell metastasis via activating STARD13-correlated ceRNA network［J］.Mol Pharm,2018,15(6):2123-2132.
[22]ZHOU XJ,WU J,SHI L,et al.PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer［J］.J Exp Clin Cancer Res,2017,36(1):149.
[23]CHEN Y,QIN H,ZHENG L.Research progress on RNA-binding proteins in breast cancer［J］.Front Oncol,2022,12:974523.
[24]HUANG W,WEI XL,NI W,et al.The expression of RNA-binding protein RBM38 decreased in renal cell carcinoma and represses renal cancer cell proliferation,migration,and invasion［J］.Tumour Biol,2017,39(5):1010428317701635.
[25]HAYAKAWA A,SAITOH M,MIYAZAWA K.Dual roles for epithelial splicing regulatory proteins 1(ESRP1) and 2(ESRP2) in cancer progression［J］.Adv Exp Med Biol,2017,925:33-40.
[26］LU G,DUAN J,ZHOU D.Long-noncoding RNA IFNG-AS1 exerts oncogenic properties by interacting with epithelial splicing regulatory protein 2(ESRP2) in pituitary adenomas［J］.Pathol Res Pract,2018,214(12):2054-2061.
[27]JEONG HM,HAN J,LEE SH,et al.ESRP1 is overexpressed in ovarian cancer and promotes switching from mesenchymal to epithelial phenotype in ovarian cancer cells ［J］.Oncogenesis,2017,6(10):e389.
[28]MUNKLEY J,LI L,KRISHNAN SRG,et al.Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer［J］.Elife,2019,8:e47678.
[29]MIZUTANI A,KOINUMA D,SEIMIYA H, et al.The Arkadia-ESRP2 axis suppresses tumor progression:analyses in clear-cell renal cell carcinoma［J］.Oncogene,2016,35(27):3514-3523.
[30]PERRON G,JANDAGHI P,SOLANKI S,et al.A general framework for interrogation of mRNA stability programs identifies RNA-binding proteins that govern cancer transcriptomes［J］.Cell Rep,2018,23(6):1639-1650.
[31]YANG F,ZHOU Q,MENG L,et al.IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype［J］.Medicine(Baltimore),2019,98(27):e16009.
[32]BURDELSKI C,JAKANI-KARIMI N,JACOBSEN F,et al.IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features:A tissue microarray study on 8,877 human cancers and normal tissues［J］.Oncol Rep,2018,39(1):3-12.
[33]XIE X,LIN J,FAN X,et al.LncRNA CDKN2B-AS1 stabilized by IGF2BP3 drives the malignancy of renal clear cell carcinoma through epigenetically activating NUF2 transcription［J］.Cell Death Dis,2021,12(2):201.
[34]TSCHIRDEWAHN S,PANIC A,PULLEN L,et al.Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma［J］.Int J Cancer,2019,145(2):531-539.
[35]CHEN L,XIE Y,LI X,et al.Prognostic value of high IMP3 expression in solid tumors:a meta-analysis［J］.Onco Targets Ther,2017,10:2849-2863.
[36]BRAUBTF,WINSLOW S,LAMPE S,et al.The RNA-binding protein HuR inhibits expression of CCL5 and limits recruitment of macrophages into tumors［J］.Mol Carcinog,2017,56(12):2620-2629.
[37]YANG F,HU A,LI D,et al.Circ-HuR suppresses HuR expression and gastric cancer progression by inhibiting CNBP transactivation［J］.Mol Cancer,2019,18(1):158.
[38]BRODY JR,DIXON DA.Complex HuR function in pancreatic cancer cells［J］.Wiley Interdiscip Rev RNA,2018,9(3):e1469.
[39]LIU Y,CHEN X,CHENG R,et al.The Jun/miR-22/HuR regulatory axis contributes to tumourigenesis in colorectal cancer［J］.Mol Cancer,2018,17(1):11.
[40]张凯琳，汪书华，石松，等.HuR基因克隆及其在肝癌细胞中的表达［J］.现代肿瘤医学，2018，26（1）：1-4.
ZHANG KL,WANG SH,SHI S,et al.HuR gene clone and construction of its eukaryotic expressional vector［J］.Modern Oncology，2018，26（1）：1-4.
[41]ZHANG Y,YANG L,LING C,et al.HuR facilitates cancer stemness of lung cancer cells via regulating miR-873/CDK3 and miR-125a-3p/CDK3 axis［J］.Biotechnol Lett,2018,40(4):623-631.
[42]VLASOVA-ST LOUIS I,BOHJANEN PR.Post-transcriptional regulation of cytokine and growth factor signaling in cancer［J］.Cytokine Growth Factor Rev,2017,33:83-93.
[43]MIYATA Y,MITSUNARI K,AKIHIRO A,et al.Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer［J］.Oncol Lett,2017,13(2):811-818.
[44]GUO L,LOUIS IV,BOHJANEN PR.Post-transcriptional regulation of cytokine expression and signaling［J］.Curr Trends Immunol,2018,19:33-40.
[45]SU CT,SEE DHW,HUANG JW.Lipid-based nanocarriers in renal RNA therapy［J］.Biomedicines,2022,10(2):283.
[46]LUO L,WANG Y,YIN Y, et al.Effects of NOB1 on the pathogenesis of osteosarcoma and its expression on the chemosensitivity to cisplatin［J］.Oncol Lett,2018,15(3):3548-3551.
[47]KE W,LU Z,ZHAO X.NOB1:A potential biomarker or target in cancer［J］.Curr Drug Targets,2019,20(10):1081-1089.
[48]DAI H,HOU K,CAI Z,et al.Low-level miR-646 in colorectal cancer inhibits cell proliferation and migration by targeting NOB1 expression［J］.Oncol Lett,2017,14(6):6708-6714.
[49]MENDES MI,GREEN LMC,BERTINI E,et al.RARS1-related hypomyelinating leukodystrophy:Expanding the spectrum［J］.Ann Clin Transl Neurol,2020,7(1):83-93.
[50]JIAO M,GUO H,CHEN Y,et al.DARS-AS1 promotes clear cell renal cell carcinoma by sequestering miR-194-5p to up-regulate DARS［J］.Biomed Pharmacother,2020,128:110323.
[51]PADIAL-MOLINA M,DE BUITRAGO JG,SAINZ-URRUELA R,et al.Expression of musashi-1 during osteogenic differentiation of oral MSC:An in vitro study［J］.Int J Mol Sci,2019,20(9):2171.
[52]KUDINOV AE,KARANICOLAS J,GOLEMIS EA,et al.Musashi RNA-binding proteins as cancer drivers and novel therapeutic targets［J］.Clin Cancer Res,2017,23(9):2143-2153.
[53]XIAO R,YU Y,SHEN S,et al.Musashi1 promotes tumor metastasis and is a prognostic marker for renal carcinoma［J］.Int J Clin Exp Pathol,2019,12(1):313-319.
[54]HO TH,KAPUR P,ECKEL-PASSOW JE,et al.Multicenter validation of enhancer of zeste homolog 2 expression as an independent prognostic marker in localized clear cell renal cell carcinoma［J］.J Clin Oncol,2017,35(32):3706-3713.
[55]ZHANG D,YANG XJ,LUO QD,et al.EZH2 enhances the invasive capability of renal cell carcinoma cells via activation of STAT3［J］.Mol Med Rep,2018,17(3):3621-3626.
[56]ZHAO Y,DHANI S,ZHIVOTOVSKY B.Unveiling caspase-2 regulation by non-coding RNAs［J］.Cell Death Dis,2022,13(9):834.
[57]ZHU Y,LIU X,WANG Y,et al.DMDRMR promotes angiogenesis via antagonizing DAB2IP in clear cell renal cell carcinoma［J］.Cell Death Dis,2022,13(5):456.
[58]EICHENAUER T,SIMMENDINGER L,FRAUNE C,et al.High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma［J］.World J Urol,2020,39(2):481-490.
[59]KIM TH,TSANG B,VERNON RM,et al.Phospho-dependent phase separation of FMRP and CAPRIN1 recapitulates regulation of translation and deadenylation［J］.Science,2019,365(6455):825-829.
[60]AWASTHI S,CHAKRAPANI B,MAHESH A,et al.DDX39B promotes translation through regulation of pre-ribosomal RNA levels［J］.RNA Biol,2018,15(9):1157-1166.
[61]MENG T,HUANG R,ZENG Z,et al.Identification of prognostic and metastatic alternative splicing signatures in kidney renal clear cell carcinoma［J］.Front Bioeng Biotechnol,2019,7:270.
[62]WU J,YANG J,CHO WC,et al.Argonaute proteins:Structural features,functions and emerging roles［J］.J Adv Res,2020,24:317-324.
[63]LI W,MARTINEZ-USEROS J,GARCIA-CARBONERO N,et al.The clinical significance of PIWIL3 and PIWIL4 expression in pancreatic cancer［J］.J Clin Med,2020,9(5):1252.
[64]LI W,MARTINEZ-USEROS J,GARCIA-CARBONERO N,et al.The prognosis value of PIWIL1 and PIWIL2 expression in pancreatic cancer［J］.J Clin Med,2019,8(9):1275.
[65]XIE K,ZHANG K,KONG J,et al.Cancer-testis gene PIWIL1 promotes cell proliferation,migration,and invasion in lung adenocarcinoma［J］.Cancer Med,2018,7(1):157-166.
[66]YAO J,XIE M,MA X,et al.PIWI-interacting RNAs in cancer:Biogenesis,function,and clinical significance［J］.Front Oncol,2022,12:965684.
[67]STOHR CG,STEFFENS S,POLIFKA I,et al.Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients［J］.Sci Rep,2019,9(1):1741.
[68]LIU Q,LIU N,SHANGGUAN Q,et al.LncRNA SAMD12-AS1 promotes cell proliferation and inhibits apoptosis by interacting with NPM1［J］.Sci Rep,2019,9(1):11593.
[69]WANG Q,ZHANG Y,WANG M,et al.The landscape of multiscale transcriptomic networks and key regulators in Parkinson's disease［J］.Nat Commun,2019,10(1):5234.
[70]DILER SB,POLAT F,BINGOL G.The MNS16A VNTR polymorphism of the TERT gene in bladder cancer［J］.Turk J Urol,2019,46(1):44-49.
[71]MITCHELL TJ,ROSSI SH,KLATTE T,et al.Genomics and clinical correlates of renal cell carcinoma［J］.World J Urol,2018,36(12):1899-1911.
[72]MURUGAN P,JIA L,DINATALE RG,et al.Papillary renal cell carcinoma:a single institutional study of 199 cases addressing classification,clinicopathologic and molecular features,and treatment outcome［J］.Mod Pathol,2022,35(6):825-835.
[73]CASUSCELLI J,BECERRA MF,MANLEY BJ,et al.Characterization and impact of TERT promoter region mutations on clinical outcome in renal cell carcinoma［J］.Eur Urol Focus,2019,5(4):642-649.
[74]WU D,ZHU G,ZENG J,et al.Genetic variations in TERC and TERT genes are associated with renal cell carcinoma risk in a Chinese Han population［J］.Oncotarget,2017,8(44):76832-76842.